Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning

Jamie H. Zao, Tal Schechter, Wenchao Jessica Liu, Sandra Gerges, Adam Gassas, R. Maarten Egeler, Eyal Grunebaum, L. Lee Dupuis
2015 Biology of Blood and Marrow Transplantation  
Achievement of a busulfan area-under-the-concentration versus time curve (AUC) of 900 to 1500 mM$min is associated with improved hematopoietic stem cell transplant (HSCT) outcomes. Multiple pediatric busulfan dosing guidelines aim to achieve this target. The authors' objective was to describe the AUCs achieved after simulated dosing using available pediatric i.v. busulfan dosing guidelines. The health records of children who received i.v. busulfan for HSCT conditioning at The Hospital for Sick
more » ... hildren were reviewed. Busulfan AUCs were calculated for each patient based on plasma busulfan concentrations using either a 1-compartment model or a validated limited-sampling strategy. Published pediatric busulfan dosing guidelines were identified. Initial busulfan doses were determined for all patients using each dosing guideline and total body weight (TBW). For overweight patients (TBW-to-ideal body weight [IBW] ! 1.25), initial busulfan doses were also determined using IBW and adjusted IBW (IBW adj ). The resulting AUCs were simulated. The proportion of subjects (TBW/IBW < 1.25, TBW/IBW ! 1.25, and infants) with an AUC within target (900 to 1500 mM$min) after dosing simulation with each guideline was compared. One hundred eleven children (mean age, 6.2 years [SD, AE5.2]) who received i.v. busulfan were included. When dosing with each of the 12 i.v. busulfan dosing guidelines identified was simulated using TBW in 97 non-overweight patients, the proportion of patients with an AUC within the target range varied from 51% to 74% and from 45% to 64% in infants. Use of IBW or IBW adj to calculate initial busulfan doses in overweight children improved the performance of most guidelines. Current busulfan dosing guidelines vary in their ability to achieve AUCs within the target range. For children who are not overweight, we recommend 1 of 3 high-performing guidelines that allow individualization of the target busulfan AUC. Use of either IBW or IBW adj in overweight children improves the performance of most guidelines. Regardless of the guideline used, therapeutic drug monitoring is essential to verify achievement of the target AUC. Ó
doi:10.1016/j.bbmt.2015.05.006 pmid:25977229 fatcat:ajtvqp2mbbe4xgekb76g7t5s3q